Trial Profile
A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India) based regimen in metastatic gastric adenocarcinoma patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 20 Jan 2024 Results assessing safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 New trial record